Altre lingue Terns Pharmaceuticals, Inc.

Azioni

TERN

US8808811074

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 05/07/2024			Variaz. 5gg	Var. 1 gen.
6,81 ^USD	-0,73%		0,00%	+4,93%

22/06	Terns Pharmaceuticals, Inc. presenta nuovi dati preclinici a sostegno di TERN-501 in combinazione con un agonista GLP-1R per l'obesità	CI
13/05	Terns Pharmaceuticals, Inc. riporta i risultati degli utili per il primo trimestre conclusosi il 31 marzo 2024	CI

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

Terns Pharmaceuticals Highlights New Preclinical Data Supporting TERN-501 in Combination with a GLP-1R Agonist for Obesity at the ADA’s 84th Annual Scientific Sessions and Upcoming Conference Participation	22/06
Terns Pharmaceuticals Highlights New Preclinical Data Supporting TERN-501 in Combination with a GLP-1R Agonist for Obesity at the ADA’s 84th Annual Scientific Sessions and Upcoming Conference Participation	22/06
Terns Pharmaceuticals, Inc. Presents New Preclinical Data Supporting TERN-501 in Combination with A GLP-1R Agonist for Obesity	22/06
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)	03/06
Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences	30/05
TERNS PHARMACEUTICALS TO PARTICIPATE IN UBS OBESITY THERAPEUTICS DAY	20/05
Terns Pharmaceuticals to Participate in UBS Obesity Therapeutics Day	17/05
Terns Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	13/05
Terns Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Updates	13/05
Terns Pharmaceuticals : Corporate Presentation May 2024	13/05
Terns Pharmaceuticals Announces Leadership Changes	08/05
Terns Pharmaceuticals Announces Leadership Changes	08/05
Terns Pharmaceuticals, Inc. Announces Executive Changes	08/05
Terns Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference 2024	07/05
TERNS PHARMACEUTICALS REPORTS INDUCEMENT GRANT TO NEW EMPLOYEE UNDER NASDAQ LISTING RULE 5635(4)	06/05
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)	03/05
Terns Pharmaceuticals : Corporate Presentation April 2024	29/04
Terns Pharmaceuticals Announces Data from Ongoing Phase 1 Pharmacokinetic Study of Allosteric BCR-ABL Inhibitor TERN-701 in Adult Healthy Volunteers and Highlights Potential for Competitive Differentiation	29/04
Terns Pharmaceuticals, Inc. Announces Data from Ongoing Phase 1 Pharmacokinetic Study of Allosteric BCR-ABL Inhibitor Tern-701 in Adult Healthy Volunteers and Highlights Potential for Competitive Differentiation	29/04
Terns Pharmaceuticals Appoints Melita Sun Jung as Chief Business Officer	10/04

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Terns Pharmaceuticals, Inc.

Azioni

TERN

US8808811074

Altre lingue

Filtri